2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

K562 tumor cells

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

10

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13062
    Daunorubicin hydrochloride
    35+ Cited Publications

    Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride

    		 Topoisomerase DNA/RNA Synthesis ADC Payload Bacterial Autophagy Apoptosis Antibiotic Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin hydrochloride
  • HY-13062A
    Daunorubicin
    35+ Cited Publications

    Daunomycin; RP 13057; Rubidomycin

    		 Topoisomerase DNA/RNA Synthesis ADC Payload Autophagy Bacterial Antibiotic Apoptosis Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin
  • HY-G0017
    N-Desmethyl imatinib
    1 Publications Verification

    Norimatinib; Imatinib metabolite N-Desmethyl imatinib; CGP 74588

    		 Drug Metabolite P-glycoprotein Apoptosis Neurological Disease Cancer
    N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib shows significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) models with mild SARS-CoV-2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
    N-Desmethyl imatinib
  • HY-153415
    PROTAC BCR-ABL Degrader-1

    		PROTACs Bcr-Abl Cancer
    PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces Bcr-Abl degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer .
    PROTAC BCR-ABL Degrader-1
  • HY-116392D
    PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Apoptosis Cancer
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research .
    PDMP hydrochloride
  • HY-G0017S
    N-Desmethyl imatinib-d8

    Norimatinib-d8; Imatinib metabolite N-Desmethyl imatinib-d8; CGP 74588-d8

    		 Isotope-Labeled Compounds Drug Metabolite P-glycoprotein Apoptosis Neurological Disease Cancer
    N-Desmethyl imatinib-d8 is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
    N-Desmethyl imatinib-d8
  • HY-W231513
    MASTL/Aurora A-IN-1

    		MASTL Ser/Thr Protease Aurora Kinase Cancer
    MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .
    MASTL/Aurora A-IN-1
  • HY-W419589
    Xanthomicrol

    		COX NO Synthase Interleukin Related Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Xanthomicrol is extracted from the resin of the plant called Chinese bellflower (a member of the Scrophulariaceae family) and is a monoamine oxidase (MAOs) inhibitor. Xanthomicrol has anti-tumor and anti-inflammatory properties, with IC50 values of 0.88 and 1.69 μg/mL in HL60 and K562 cells. Xanthomicrol's the main metabolite of 5DT in mouse colon, and it can reduce levels of iNOS protein and mRNA, as well as COX-2 protein levels. Additionally, Xanthomicrol decreases the production of the pro-inflammatory cytokine IL-1β and induces the expression of the antioxidant enzyme HO-1 .
    Xanthomicrol
  • HY-N9339
    Norglaucine

    (+)-Norglaucine

    		 Others Cancer
    Norglaucine ((+)-Norglaucine), a cytotoxic alkaloid, exhibits cytotoxicity towards the tumor cell lines B16-F10, HepG2, K562 and HL-60 cells .
    Norglaucine
  • HY-177768
    HDAC-IN-96

    		HDAC Apoptosis Cancer
    HDAC-IN-96 (Compound 3f) is a selective HDAC1/2 inhibitor with IC50 values of 457.1 and 433.7 nM. HDAC-IN-96 has strong inhibitory activity against multiple hematological tumor cells (RS4;11, K562, RPMI-8226, U266), with IC50 values ranging from 2.11 to 5.35 μM. HDAC-IN-96 can induce cancer cells apoptosis and S phase arrest. HDAC-IN-96 can be used for the research of cancer, such as acute lymphoblastic leukemia .
    HDAC-IN-96
  • HY-163673
    Glucocorticoid receptor modulator 4

    		Glucocorticoid Receptor Drug-Linker Conjugates for ADC Inflammation/Immunology
    Glucocorticoid receptor modulator 4 (Compound DL5) is a conjugate of a linker and a glucocorticoid receptor modulator. Glucocorticoid receptor modulator 4 exhibits GRE Reporter activity in mTNF expressing K562 cell with an EC50 of 40 μM. Glucocorticoid receptor modulator 4 binds with an anti-tumor necrosis factor (TNF) antibody, and exhibits anti-inflammtory activity against arthritis in mouse models .
    Glucocorticoid receptor modulator 4
  • HY-122724
    IQDMA

    		Apoptosis Cancer
    IQDMA is an anti-tumor compound. IQDMA can induce apoptosis in tumor cells, such as K562 cells .
    IQDMA
  • HY-N14523
    Gilvusmycin

    		Antibiotic Bacterial Infection
    Gilvusmycin is an antibiotic with strong anti-tumor activity. Gilvusmycin can inhibit P388, K562, A431 and MKN28 cells with IC50s (ng/mL) of 0.08, 0.86, 0.72 and 0.75, respectively .
    Gilvusmycin
  • HY-N14415
    Cochleamycin A

    		Bacterial Infection Cancer
    Cochleamycin A showed strong inhibitory activity against tumor cells, with IC50s (μg/mL) of P388, HL60, K562, COL0205 and HT29 cells of 1.6, 14.0, 6.2, 16.5 and 19.1, respectively. Cochleamycin A also has anti-Gram-positive bacteria activity .
    Cochleamycin A
  • HY-111193
    Declopramide

    3-Chloroprocainamide

    		 NF-κB Apoptosis Cancer
    Declopramide (3-Chloroprocainamide) is an orally active antitumor agent, which inhibits proliferation of cancer cells HL60 and K562, and inhibits tumor growth of human brain astrocytoma (T24) in mouse model. Declopramide induces apoptosis, inhibits NF-κB through inhibition of IκBα degradation. Declopramide serves also as chemosensitizer in research .
    Declopramide
  • HY-N14135
    Cystothiazole A

    		Fungal Infection Cancer
    Cystothiazole A has antifungal activity. Cystothiazole A can inhibit candida albicans, saccharomyces cerevisiae and aspergillus smoke with MIC values of 0.4 μg/mL, 0.1 μg/mL and 1.6 μg/mL, respectively. Cystothiazole A also inhibits human tumor cell, such as HPT-116 and K562 cells with MIC values of 130 ng/mL and 110 ng/mL, respectively. Cystothiazole A has no anti-bacterial effect .
    Cystothiazole A
  • HY-161324
    Tubulin degrader 1

    		Microtubule/Tubulin Cancer
    Tubulin degrader 1 (Compound 5i) is a BML284 (HY-19987) derivative that is an orally active colchicine-site noncovalent tubulin degradation agent with IC50 values ranging from 0.02 to 0.05 μM against the five tumor cell lines (Hela, HCT116, MCF-7, K562 and Molm-13). Tubulin degrader 1 has antiproliferative activity that effectively suppressed tumor growth .
    Tubulin degrader 1
  • HY-172364
    PLK1-IN-12

    		Polo-like Kinase (PLK) Cancer
    PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .
    PLK1-IN-12
  • HY-108876
    Daunorubicin citrate

    Daunomycincitrate; RP 13057citrate; Rubidomycincitrate

    		 Topoisomerase DNA/RNA Synthesis ADC Payload Autophagy Bacterial Antibiotic Apoptosis Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin citrate
  • HY-13062R
    Daunorubicin hydrochloride (Standard)

    Daunomycin hydrochloride (Standard); RP 13057 hydrochloride (Standard); Rubidomycin hydrochloride (Standard)

    		 Reference Standards Topoisomerase DNA/RNA Synthesis ADC Payload Bacterial Autophagy Apoptosis Antibiotic Infection Neurological Disease Cancer
    Daunorubicin (hydrochloride) (Standard) is the analytical standard of Daunorubicin (hydrochloride). This product is intended for research and analytical applications. Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin hydrochloride (Standard)
  • HY-161694
    DNMT1-IN-3

    		DNA Methyltransferase Cancer
    DNMT1-IN-3 (compound 7t-S) is an effective DNA methyltransferase 1 (DNMT1) inhibitor with an IC50 value of 0.777 μM and a KD value of 0.183 μM. DNMT1-IN-3 can bind to the methyl donor S-adenosyl-l-methionine (SAM) site in DNMT1. DNMT1-IN-3 can inhibit cell proliferation in K562 cells by inducing cells apoptosis and arresting cell cycle at G0 / G1 phase, which has the potential to be used for the research of hematologic tumor .
    DNMT1-IN-3
  • HY-G0017A
    N-Desmethyl imatinib mesylate

    Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate; CGP 74588 mesylate

    		 Drug Metabolite P-glycoprotein Apoptosis Neurological Disease Cancer
    N-Desmethyl imatinib mesylate (Norimatinib mesylate) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib mesylate binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib mesylate induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib mesylate exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib mesylate can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
    N-Desmethyl imatinib mesylate
  • HY-G0017S1
    N-Desmethyl imatinib-d4

    Norimatinib-d4; Imatinib metabolite N-Desmethyl imatinib-d4; CGP 74588-d4

    		 Isotope-Labeled Compounds Drug Metabolite P-glycoprotein Apoptosis Neurological Disease Cancer
    N-Desmethyl imatinib-d4 is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
    N-Desmethyl imatinib-d4
  • HY-G0017R
    N-Desmethyl imatinib (Standard)

    Norimatinib (Standard); Imatinib metabolite N-Desmethyl imatinib (Standard); CGP 74588 (Standard)

    		 Reference Standards Drug Metabolite P-glycoprotein Apoptosis Others
    N‑Desmethyl imatinib (Standard) is the analytical standard of N‑Desmethyl imatinib (Norimatinib) (HY-G0017R). This product is intended for research and analytical applications. N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
    N-Desmethyl imatinib (Standard)
  • HY-180968
    GMB-805

    		PROTACs Bcr-Abl Cancer
    GMB-805 is a BCR-Abl PROTAC degrader with a DC50 of 30 nM in K562 cells. GMB-805 exerts antiproliferative activity in K562 cells. GMB-805 exhibits potent anti-tumor activity with favorable safety profile in vivo. GMB-805 can be used for chronic myeloid leukemia research .
    GMB-805
  • HY-180969
    SIAIS056

    		PROTACs Bcr-Abl Cancer
    SIAIS056 is a BCR-ABL PROTAC degrader with a DC50 value of 0.18 nM. SIAIS056 time-dependently inhibits the BCR-ABL signaling pathway, accompanied by decreased phosphorylation of BCR-ABL and the downstream molecules STAT5 and CRKL in K562 cells. SIAIS056 induces the degradation of several clinically relevant resistance-conferring mutations of BCR-ABL. SIAIS056 exhibits anti-proliferative activity and induces substantial tumor regression in K562 xenograft models. SIAIS056 can be used for leukemia research .
    SIAIS056
  • HY-N1691
    21-Episerratriol

    3-Epilycoclavanol

    		 Others Cancer
    3-Epilycoclavanol (3-Epilycoclavanol) is a triterpenoid antitumor agent that can be extracted from the dried whole plant of Lycopodium japonicum (a plant of the Lycopodium genus in the Lycopodiaceae family). 3-Epilycoclavanol inhibits human tumor A549 and K562 cell lines at concentrations of 10-100 μg/mL .
    21-Episerratriol
  • HY-N16684
    Clausarin

    		P-glycoprotein Cancer
    Clausarin is a selective inhibitor of P-glycoprotein (P-gp), inhibiting P-gp-mediated drug efflux. Clausarin significantly inhibits Daunorubicin (HY-13062A) efflux in K562/R7 human leukemia cells overexpressing P-gp (with Cyclosporin A (HY-B0579) as a positive control). Clausarin can be naturally extracted from the roots of Citrus sinensis (sweet orange) and can be used in research related to overcoming multidrug resistance (MDR) in tumors .
    Clausarin
  • HY-172748
    9β-Hydroxyhexahydrocannabinol

    		Drug Derivative Neurological Disease Cancer
    9β-Hydroxyhexahydrocannabinol is a synthetic cannabinoid derivative. 9β-Hydroxyhexahydrocannabinol exhibits cytotoxicity against various tumor cell lines, such as HCT-116, MCF-7, K562, MIAPaCa-2, PANC-1, A549, PC-3 and SW-620, with IC50 values ranging from 15.23 to 33.74 μM. 9β-Hydroxyhexahydrocannabinol can be used in the study of cancer .
    9β-Hydroxyhexahydrocannabinol
  • HY-N16816
    Rubescensin J

    		Others Others
    Rubescensin J is a known ent-abietane diterpenoid that can be found in the leaves of Isodon rubescens var. rubescens and is inactive in cytotoxicity against cancer cells .
    Rubescensin J
  • HY-182506
    Azimexon

    BM 12.531

    		 Biochemical Assay Reagents Inflammation/Immunology Cancer
    Azimexon (BM 12.531) is an orally active immunomodulator with radioprotective and antitumor activities. Azimexon prolongs survival in multiple mouse models, enhances immunity and hematopoiesis, and alleviates radiation injury and tumor metastasis. Azimexon causes reversible hemolytic anemia in rats and dogs, and exerts therapeutic activity against adjuvant-induced arthritis in rats. Azimexon can be used for the research of lung carcinoma, leukemia, multiple myeloma, lung tumor, arthritis, breast cancer and AIDS‑related complex .
    Azimexon

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: